Clinical trials: Schizophrenia Disorder
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Comparative Bioavailability of Risperidone.
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
- Trial name
- NCT05179525
- Testing
- Risperidone ISM® 100 mg, Risperdal 4mg Tablet
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia and Related Disorders, Major Depressive Disorder
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros.
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Trial name
- INTENSIFY (NCT05603104)
- Testing
- Clozapine, Esketamine Nasal Product, Escitalopram
- Where
- Israel
- Volunteers
- 1,254 people
- Sponsor
- Dr. Inge Winter
Schizophrenia, Schizoaffective Disorder
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- TrypNAC-II (NCT04013555)
- Testing
- N-acetylcysteine (NAC), Tryptophan
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Imaging Cannabinoid CB1 Receptors in Schizophrenia
Background: The CB1 receptor is a protein in the brain that is targeted by the active ingredients in cannabis (marijuana). Brain systems that react to cannabis may be involved in the causes and symptoms of schizophrenia and…
- Trial name
- NCT01063335
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Cognition
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
- Trial name
- NCT00654706
- Testing
- Sertindole, Quetiapine
- Where
- 26 sites in United States
- Volunteers
- 264 people
- Sponsor
- H. Lundbeck A/S
Psychosis, Bipolar Disorder
Young People and Illness Management and Recovery (IMR)
The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed…
- Conditions
- Psychosis, Bipolar Disorder, Other Diagnoses and Conditions
- Trial name
- NCT04778085
- Testing
- Illness management and recovery, Semi-structured interviews
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- University Hospital, Akershus
Psychosis
A Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders
The study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders.
- Trial name
- TREPP (NCT05719116)
- Testing
- Physical exercise
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Solli Distriktspsykiatriske Senter
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Emotional Dysfunction, Psychosis
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
The principal aim of the study is to assess the efficacy of the Unified Protocol (UP) for the treatment of the comorbid symptomatology of patients with Ultra High Risk (UHR) for psychosis.
- Trial name
- NCT04929938
- Testing
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia, Schizotypal and Delusional Disorders
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
- Trial name
- NCT03554655
- Testing
- Momentum app
- Where
- 7 sites in Denmark
- Volunteers
- 194 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Healthy
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
- Trial name
- NCT00581243
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
The Effects of Nicotine on Cognition in Schizophrenia
Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We…
- Trial name
- NCT00383747
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with…
- Trial name
- NCT05545111
- Testing
- NBI-1117568
- Where
- 15 sites in United States
- Volunteers
- 210 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Schizophrenia, Schizoaffective Disorder
Clinical Trial of AVL-3288 in Schizophrenia Patients
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients…
- Trial name
- NCT02978599
- Testing
- AVL-3288
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- New York State Psychiatric Institute